Some thiocarbamoyl based novel anticathepsin agents.

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Pharmacology

Background:

• Cathepsins are crucial enzymes in extracellular matrix degradation and protein turnover, implicated in various degenerative disorders.
• Elevated cathepsin activity and reduced inhibitor levels are observed in diseased tissues, highlighting their therapeutic relevance.
• Peptide-based cathepsin inhibitors face challenges like oral instability and immunogenicity, necessitating the development of non-peptide alternatives.

Purpose of the Study:

• To investigate the structure-activity relationships (SAR) of novel non-peptide cathepsin inhibitors.
• To identify potential non-peptide agents for therapeutic intervention in cathepsin-related disorders.
• To provide a detailed SAR analysis based on in-vitro inhibition data.

Main Methods:

• Synthesis of a library of thiocarbamoyl-based non-peptide compounds.
• In-vitro inhibition assays to evaluate the efficacy of synthesized compounds against cathepsins.
• Detailed structure-activity relationship analysis of the tested inhibitors.

Main Results:

• Identification of specific structural features contributing to potent cathepsin inhibition.
• Demonstration of the SAR for a series of non-peptide thiocarbamoyl inhibitors.
• Establishment of a foundation for the rational design of improved non-peptide cathepsin inhibitors.

Conclusions:

• Non-peptide thiocarbamoyl compounds show promise as cathepsin inhibitors.
• The SAR data provides valuable insights for developing orally stable and non-immunogenic therapeutic agents.
• This research contributes to the ongoing effort to find effective treatments for degenerative diseases involving cathepsins.